Global Adalimumab Biosimilar Market Research Report 2021

1 Adalimumab Biosimilar Market Overview

• 1.1 Product Overview and Scope of Adalimumab Biosimilar
• 1.2 Adalimumab Biosimilar Segment by Type
  • 1.2.1 Global Adalimumab Biosimilar Sales Growth Rate Comparison by Type (2021-2027)
  • 1.2.2 Tablet
  • 1.2.3 Oral Solution
• 1.3 Adalimumab Biosimilar Segment by Application
  • 1.3.1 Adalimumab Biosimilar Sales Comparison by Application: (2021-2027)
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Retail Pharmacy
  • 1.3.4 Online Pharmacy
• 1.4 Global Adalimumab Biosimilar Market Size Estimates and Forecasts
  • 1.4.1 Global Adalimumab Biosimilar Revenue 2016-2027
  • 1.4.2 Global Adalimumab Biosimilar Sales 2016-2027
  • 1.4.3 Adalimumab Biosimilar Market Size by Region: 2016 Versus 2021 Versus 2027

2 Adalimumab Biosimilar Market Competition by Manufacturers

• 2.1 Global Adalimumab Biosimilar Sales Market Share by Manufacturers (2016-2021)
• 2.2 Global Adalimumab Biosimilar Revenue Market Share by Manufacturers (2016-2021)
• 2.3 Global Adalimumab Biosimilar Average Price by Manufacturers (2016-2021)
• 2.4 Manufacturers Adalimumab Biosimilar Manufacturing Sites, Area Served, Product Type
• 2.5 Adalimumab Biosimilar Market Competitive Situation and Trends
  • 2.5.1 Adalimumab Biosimilar Market Concentration Rate
  • 2.5.2 The Global Top 5 and Top 10 Largest Adalimumab Biosimilar Players Market Share by Revenue
  • 2.5.3 Global Adalimumab Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Adalimumab Biosimilar Retrospective Market Scenario by Region

• 3.1 Global Adalimumab Biosimilar Retrospective Market Scenario in Revenue by Region: 2016-2021
• 3.2 Global Adalimumab Biosimilar Retrospective Market Scenario in Sales by Region: 2016-2021
• 3.3 North America Adalimumab Biosimilar Market Facts & Figures by Country
  • 3.3.1 North America Adalimumab Biosimilar Sales by Country
  • 3.3.2 North America Adalimumab Biosimilar Revenue by Country
  • 3.3.3 U.S.
  • 3.3.4 Canada
• 3.4 Europe Adalimumab Biosimilar Market Facts & Figures by Country
  • 3.4.1 Europe Adalimumab Biosimilar Sales by Country
  • 3.4.2 Europe Adalimumab Biosimilar Revenue by Country
  • 3.4.3 Germany
  • 3.4.4 France
  • 3.4.5 U.K.
  • 3.4.6 Italy
  • 3.4.7 Russia
• 3.5 Asia Pacific Adalimumab Biosimilar Market Facts & Figures by Region
  • 3.5.1 Asia Pacific Adalimumab Biosimilar Sales by Region
  • 3.5.2 Asia Pacific Adalimumab Biosimilar Revenue by Region
  • 3.5.3 China
  • 3.5.4 Japan
  • 3.5.5 South Korea
  • 3.5.6 India
  • 3.5.7 Australia
  • 3.5.8 Taiwan
  • 3.5.9 Indonesia
  • 3.5.10 Thailand
  • 3.5.11 Malaysia
  • 3.5.12 Philippines
  • 3.5.13 Vietnam
• 3.6 Latin America Adalimumab Biosimilar Market Facts & Figures by Country
  • 3.6.1 Latin America Adalimumab Biosimilar Sales by Country
  • 3.6.2 Latin America Adalimumab Biosimilar Revenue by Country
  • 3.6.3 Mexico
  • 3.6.4 Brazil
  • 3.6.5 Argentina
• 3.7 Middle East and Africa Adalimumab Biosimilar Market Facts & Figures by Country
  • 3.7.1 Middle East and Africa Adalimumab Biosimilar Sales by Country
  • 3.7.2 Middle East and Africa Adalimumab Biosimilar Revenue by Country
  • 3.7.3 Turkey
  • 3.7.4 Saudi Arabia
  • 3.7.5 U.A.E

4 Global Adalimumab Biosimilar Historic Market Analysis by Type

• 4.1 Global Adalimumab Biosimilar Sales Market Share by Type (2016-2021)
• 4.2 Global Adalimumab Biosimilar Revenue Market Share by Type (2016-2021)
• 4.3 Global Adalimumab Biosimilar Price by Type (2016-2021)

5 Global Adalimumab Biosimilar Historic Market Analysis by Application

• 5.1 Global Adalimumab Biosimilar Sales Market Share by Application (2016-2021)
• 5.2 Global Adalimumab Biosimilar Revenue Market Share by Application (2016-2021)
• 5.3 Global Adalimumab Biosimilar Price by Application (2016-2021)

6 Key Companies Profiled

• 6.1 AET BioTech
  • 6.1.1 AET BioTech Corporation Information
  • 6.1.2 AET BioTech Description and Business Overview
  • 6.1.3 AET BioTech Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.1.4 AET BioTech Product Portfolio
  • 6.1.5 AET BioTech Recent Developments/Updates
• 6.2 Amgen
  • 6.2.1 Amgen Corporation Information
  • 6.2.2 Amgen Description and Business Overview
  • 6.2.3 Amgen Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.2.4 Amgen Product Portfolio
  • 6.2.5 Amgen Recent Developments/Updates
• 6.3 Boehringer Ingelheim
  • 6.3.1 Boehringer Ingelheim Corporation Information
  • 6.3.2 Boehringer Ingelheim Description and Business Overview
  • 6.3.3 Boehringer Ingelheim Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.3.4 Boehringer Ingelheim Product Portfolio
  • 6.3.5 Boehringer Ingelheim Recent Developments/Updates
• 6.4 Coherus Biosciences
  • 6.4.1 Coherus Biosciences Corporation Information
  • 6.4.2 Coherus Biosciences Description and Business Overview
  • 6.4.3 Coherus Biosciences Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Coherus Biosciences Product Portfolio
  • 6.4.5 Coherus Biosciences Recent Developments/Updates
• 6.5 Fujifilm Kyowa Kirin Biologics
  • 6.5.1 Fujifilm Kyowa Kirin Biologics Corporation Information
  • 6.5.2 Fujifilm Kyowa Kirin Biologics Description and Business Overview
  • 6.5.3 Fujifilm Kyowa Kirin Biologics Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.5.4 Fujifilm Kyowa Kirin Biologics Product Portfolio
  • 6.5.5 Fujifilm Kyowa Kirin Biologics Recent Developments/Updates
• 6.6 LG Life Sciences/Mochida Pharmaceutical
  • 6.6.1 LG Life Sciences/Mochida Pharmaceutical Corporation Information
  • 6.6.2 LG Life Sciences/Mochida Pharmaceutical Description and Business Overview
  • 6.6.3 LG Life Sciences/Mochida Pharmaceutical Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.6.4 LG Life Sciences/Mochida Pharmaceutical Product Portfolio
  • 6.6.5 LG Life Sciences/Mochida Pharmaceutical Recent Developments/Updates
• 6.7 Momenta Pharmaceuticals
  • 6.6.1 Momenta Pharmaceuticals Corporation Information
  • 6.6.2 Momenta Pharmaceuticals Description and Business Overview
  • 6.6.3 Momenta Pharmaceuticals Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.4.4 Momenta Pharmaceuticals Product Portfolio
  • 6.7.5 Momenta Pharmaceuticals Recent Developments/Updates
• 6.8 Oncobiologics
  • 6.8.1 Oncobiologics Corporation Information
  • 6.8.2 Oncobiologics Description and Business Overview
  • 6.8.3 Oncobiologics Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.8.4 Oncobiologics Product Portfolio
  • 6.8.5 Oncobiologics Recent Developments/Updates
• 6.9 Pfizer
  • 6.9.1 Pfizer Corporation Information
  • 6.9.2 Pfizer Description and Business Overview
  • 6.9.3 Pfizer Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.9.4 Pfizer Product Portfolio
  • 6.9.5 Pfizer Recent Developments/Updates
• 6.10 Samsung Bioepsis
  • 6.10.1 Samsung Bioepsis Corporation Information
  • 6.10.2 Samsung Bioepsis Description and Business Overview
  • 6.10.3 Samsung Bioepsis Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.10.4 Samsung Bioepsis Product Portfolio
  • 6.10.5 Samsung Bioepsis Recent Developments/Updates
• 6.11 Sandoz
  • 6.11.1 Sandoz Corporation Information
  • 6.11.2 Sandoz Adalimumab Biosimilar Description and Business Overview
  • 6.11.3 Sandoz Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.11.4 Sandoz Product Portfolio
  • 6.11.5 Sandoz Recent Developments/Updates
• 6.12 Zydus Cadila
  • 6.12.1 Zydus Cadila Corporation Information
  • 6.12.2 Zydus Cadila Adalimumab Biosimilar Description and Business Overview
  • 6.12.3 Zydus Cadila Adalimumab Biosimilar Sales, Revenue and Gross Margin (2016-2021)
  • 6.12.4 Zydus Cadila Product Portfolio
  • 6.12.5 Zydus Cadila Recent Developments/Updates

7 Adalimumab Biosimilar Manufacturing Cost Analysis

• 7.1 Adalimumab Biosimilar Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Key Suppliers of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
• 7.3 Manufacturing Process Analysis of Adalimumab Biosimilar
• 7.4 Adalimumab Biosimilar Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

• 8.1 Marketing Channel
• 8.2 Adalimumab Biosimilar Distributors List
• 8.3 Adalimumab Biosimilar Customers

9 Adalimumab Biosimilar Market Dynamics

• 9.1 Adalimumab Biosimilar Industry Trends
• 9.2 Adalimumab Biosimilar Growth Drivers
• 9.3 Adalimumab Biosimilar Market Challenges
• 9.4 Adalimumab Biosimilar Market Restraints

10 Global Market Forecast

• 10.1 Adalimumab Biosimilar Market Estimates and Projections by Type
  • 10.1.1 Global Forecasted Sales of Adalimumab Biosimilar by Type (2022-2027)
  • 10.1.2 Global Forecasted Revenue of Adalimumab Biosimilar by Type (2022-2027)
• 10.2 Adalimumab Biosimilar Market Estimates and Projections by Application
  • 10.2.1 Global Forecasted Sales of Adalimumab Biosimilar by Application (2022-2027)
  • 10.2.2 Global Forecasted Revenue of Adalimumab Biosimilar by Application (2022-2027)
• 10.3 Adalimumab Biosimilar Market Estimates and Projections by Region
  • 10.3.1 Global Forecasted Sales of Adalimumab Biosimilar by Region (2022-2027)
  • 10.3.2 Global Forecasted Revenue of Adalimumab Biosimilar by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources
• 12.3 Author List